Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adagrasib - Mirati Therapeutics

Next Previous
Drug Profile

Adagrasib - Mirati Therapeutics

Alternative Names: KRAZATI; MRTX 849

Latest Information Update: 02 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma; Mirati Therapeutics
  • Developer Bristol-Myers Squibb; Mirati Therapeutics; Novartis; Whitehawk Therapeutics; ZAI Lab
  • Class Acetonitriles; Antineoplastics; Halogenated hydrocarbons; Naphthalenes; Piperazines; Pyridones; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action KRAS protein inhibitors; Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Non-small cell lung cancer
  • Phase II Solid tumours
  • Preclinical Bladder cancer

Most Recent Events

  • 19 Feb 2026 Mirati Therapeutics terminates a phase I/II trial for Solid tumours (Inoperable/Unresectable, Metastatic disease, Combination therapy, Late-stage disease) in USA and Puerto Rico due to changes business objectives (PO) (NCT05578092)
  • 14 Aug 2025 Mirati Therapeutics in collaboration with M.D. Anderson Cancer Center withdraws prior to enrolment the Phase-I clinical trials in Pancreatic cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT05634525)
  • 11 Jul 2025 Incyte Corporation terminates a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Italy, Spain, United Kingdom due to a strategic business decision. There were no safety concerns contributing to this decision (PO) (NCT06039384)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top